Recent Headlines
Bold Health Partners with the University of Pennsylvania for Clinical Trial of Its Zemedy IBS App
The School of Arts and Science of the prestigious University of Pennsylvania has tendered a public invitation for suitable individuals to participate in a waitlist randomised control trial aimed at investigating the potential benefits of the Zemedy mobile app in patients with Irritable Bowel... - November 13, 2019 - Bold Health
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem
Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix. - November 09, 2019 - Global Regenerative Group
NuvOx Pharma US Patent Issuance - Radiotherapy and Chemotherapy with an Oxygen Therapeutic
NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen... - November 03, 2019 - NuvOx Therapeutics
Alzheimer’s Stem Cell Study to Renew by Alzheimer’s Awareness Month
MD Stem Cells plans to continue ACIST Alzheimer’s, Autism, Dementia study at least additional year. - October 31, 2019 - MD Stem Cells
CADASIL Eligibility in the NEST Neurologic Stem Cell Treatment Study
MD Stem Cells reports how hereditary stroke syndrome may benefit. - October 30, 2019 - MD Stem Cells
Aciont Issued Key Patent Covering the Novel Design of the Visulex Ocular Drug Delivery Device
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical program under U.S. IND. - October 12, 2019 - Aciont Inc.
Omni Health Announces CEO Resignation
Omni Health, Inc., (OTC: OMHE) Andrey Soloviev announces his resignation from the position of CEO of Omni Health, Inc. effective 08/20/2019. Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that... - September 27, 2019 - Omni Health
Cayman Awarded 1.5 Million Dollar SBIR Grant
The NIH’s National Institute of Arthritis and Musculoskeletal & Skin Diseases (NIAMS) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop its patented small molecule bone repair agent KMN-159. - September 25, 2019 - Cayman Chemical Company
Oncoheroes Biosciences Inc. and Boehringer Ingelheim International GmbH Sign Exclusive Licensing Agreement for Volasertib
Oncoheroes Biosciences Inc (“Oncoheroes”) and Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”) have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by... - September 19, 2019 - Oncoheroes Biosciences Inc.
Paras Biopharmaceuticals Successfully Develops Cytofold StructQuant® Technology for Cytoplasmic Disulphide Formation, (for Active Folding) for Complex Therapeutic Protein
Paras Biopharmaceuticals Finland Oy is pleased to announce that its proprietary technology, Cytofold StructQuant®, is established for the high-level expression of homogeneously folded disulfide bond containing proteins in the cytoplasm of E. Coli. The technology offers all cost benefits of... - September 10, 2019 - Paras Biopharmaceuticals Finland Oy
Global Regenerative Group & Kanfit3D Enter Into Distribution Partnership
Pleased to announce a new distribution partnership between Global Regenerative Group, a company which has developed extensive experience in the most advanced medical device industries, and Kanfit3D. - September 05, 2019 - Global Regenerative Group
Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets
Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to... - September 05, 2019 - Cayman Chemical Company
CrystalGenomics Receives Orphan Drug Designation from the US FDA for CG-745 in Pancreatic Cancer
CrystalGenomics, Inc. (KOSDAQ: 083790) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of... - August 30, 2019 - CrystalGenomics, Inc.
New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories
8-year Study Tracks Central Lab Performance and Identifies Covance as Leading the Way in Clinical Investigator Satisfaction. - August 13, 2019 - Life Science Strategy Group, LLC
Arteric Named a Top 100 Healthcare Marketing Agency by MM&M
Latest accolade follows a year of 30% revenue growth and thought leadership. - August 09, 2019 - Arteric
Global Regenerative Group Becomes Global Partner for Pharmaceutical Wholesaler Prosupplier GmbH Representing Their CureOs® Synthetic BONE GRAFT
Global Regenerative Group, developer and global distributor of new and innovative products in the field of Regenerative Medicine, today announces its partnership with Prosupplier GmbH, a pharmaceutical wholesaler with an experienced and specialist team, whose products include CureOs® Synthetic BONE GRAFT. - August 02, 2019 - Global Regenerative Group
Hans Kaspersetz Shares Arteric's Approaches to Leveraging Artificial Intelligence in Healthcare Marketing at Digital Pharma West
Two Case Studies Illustrate the Impact of AI on Accelerating Business, and the Insights That Result - June 23, 2019 - Arteric
Multiplex ELISAs Offer Powerful Profiling Capabilities
Cayman now offers multiplex immunoassay technology powered by Quansys Biosciences. This line of fully quantitative Q-Plex™ multiplex ELISAs and chemiluminescent Q-View™ imagers provides a highly sensitive means to simultaneously measure multiple markers using a single sample. - June 22, 2019 - Cayman Chemical Company
The OMEGATOF, a Fully Integrated Benchtop Spectrometer Instrument for High-Mass MALDI Applications with the Power of CovalX Technology Inside
CovalX has partnered with Shimadzu Scientific Instruments to offer the OMEGATOF, an integrated MALDI solution for ultra high-mass detection. With a focus on the detection of large molecules, including biotherapeutics, protein complexes, aggregates, and antibody-antigen interactions in a benchtop... - June 13, 2019 - CovalX
New Research Benchmarks Pharma’s Changing Utilization of Real-World Evidence (RWE) and Its Impact on Contract Research Organizations (CROs)
Study Tracks Utilization of Real-World Data (RWD), Real-World Evidence (RWE) and Supportive Services and Implications to CROs. - June 11, 2019 - Life Science Strategy Group, LLC
Global Regenerative Group (GRG) Announced That the Global Regenerative Academy Has Been Launched
The Global Regenerative Academy is an integral part of the Global Regenerative Group, a privately-held medical technologies company specializing exclusively on Regenerative Medicine and stem cell technologies, products, and therapies that significantly enhance the body’s natural healing ability. - June 06, 2019 - Global Regenerative Group
Matreya, LLC is Now a Part of Cayman Chemical Company to Better Serve the Lipid Community
Cayman Chemical, an industry-leading supplier of bioactive lipids, analytical standards, and contract lipidomic services, announced today that it has acquired Matreya, LLC, a lipid biochemical company located in State College, Pennsylvania, with strengths in synthesis, extraction, and purification of natural products. Matreya stocks a wide selection of high-purity sphingolipids, phospholipids, fatty acids and esters, and sterols to be used as research standards. - June 05, 2019 - Cayman Chemical Company
BPOG Extractables Testing of AdvantaPure(R)’s Key Silicone and TPE Tubing Products is Complete; Test Results Help Drug Manufacturers Compare Tubing
BioPhorum Operations Group extractables testing was recently completed on several of AdvantaPure’s tubing and hose products. The fluid transfer products are typically used in biopharm and pharmaceutical manufacturing processes. The Group’s standardized extractables test protocol was followed and performed by an independent lab and involved testing to four different exposure times as long as 70 days. The comprehensive testing was undertaken by AdvantaPure to meet customer requests. - May 31, 2019 - AdvantaPure
Arteric Advances Healthcare Marketing and Engagement Campaigns at Biopharma eMarketing Summit
President and Chief Strategist Shares Two Case Studies That Illustrate How to Leverage Artificial Intelligence to Achieve Business Goals. - May 10, 2019 - Arteric
Eurofarma Synapsis Receives Registrations Until June 21
Sustainable entrepreneurship platform in Latin America in partnership with Endeavor, encourages innovation in health area. - May 09, 2019 - Eurofarma
Reuters to Make Documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a Leading Expert
Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected the Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions. The documentary is part of... - May 07, 2019 - Paras Biopharmaceuticals Finland Oy
NanoCellect Biomedical Begins Distribution to Europe
NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced an exclusive distribution agreement with Basel, Switzerland-based Bucher Biotec AG. The agreement covers sales in Switzerland of NanoCellect’s... - May 01, 2019 - NanoCellect
MD Stem Cells New Alzheimer’s Treatment Shows Early Benefits
Initial memory improvements following ACIST stem cells may hold promise for ALZ. - April 24, 2019 - MD Stem Cells
Standigm Raises US $11.5 Million in Series B Round Funding to Advance Its AI-Powered Drug Pipelines Toward License-Out
Standigm, an AI-powered drug discovery company, has raised $11.5 million in a Series B funding round. The funds will be used to scale the AI technology platforms and advance its drug discovery pipelines for untreatable diseases. - March 29, 2019 - Standigm
Are Antioxidants the Solution to Burning and Itchy Eyes?
A recently published study in The Ocular Surface journal authored by Experimentica Ltd. in collaboration with researchers from Loyola University Chicago and the University of Missouri – Kansas City suggests that a topical antioxidant formulation can improve the pathological signs associated with dry-eye disease. - March 26, 2019 - Experimentica Ltd
Daryn Henry Joins Arteric as Creative Director
Veteran Digital Communicator Brings Decades of Award-Winning Experience to Boundary-Pushing Agency. - March 15, 2019 - Arteric
Arteric Explores Current Uses of Artificial Intelligence and Machine Learning to Accelerate Digital NPP Engagement for Biotechnology and OTC Brands
Arteric Shares Case Studies with Life Science Leaders, Illustrating Methods to Increase the Relevance and Authority of Brand Content. - March 14, 2019 - Arteric
Arteric Guides Healthcare Marketing Leaders on Practical Applications of Artificial Intelligence (AI) to Uncover Unmet Customer Needs
Two Case Studies Illustrate the Impact of AI on Accelerating Business, and the Insights That Result. - March 04, 2019 - Arteric
Standigm Launches Artificial Intelligence-Driven Drug Discovery Service at 2019 BIO-Asia International Conference in Tokyo, Japan
Standigm, a company using the advanced AI technology to drug discovery, launched the customized early drug discovery and target study service, "Standigm Insight®," at 2019 BIO-Asia International Conference in Tokyo, Japan. Standigm Insight® provides AI-driven new indication prediction and novel target analysis service for customer’s in-house products. - March 04, 2019 - Standigm
Sanyal Biotechnology Hires IQVIA / BuzzeoPDMA DEA Compliance Group
Sanyal Bio has expanded into pre-clinical and clinical contract research on cannabinoids. Sanyal Bio currently holds a DEA Schedule 1 Import License for Cannabis Extracts and THC, with applications pending for Research, Analytical and Manufacturing licenses. IQVIA's DEA Compliance group is well-respected for their expertise and Sanyal Bio looks forward to working with this reputable group going forward. - February 13, 2019 - Sanyal Biotechnology
Plant Extract Can Help Prevent Cancer Recurrence says the Beljanski Foundation
Rauwolfia Vomitoria, a Natural Plant Extract, Inhibits Cancer Stem Cells - February 08, 2019 - The Beljanski Foundation
Milestone in Cancer Stem Cell Research by Beljanski Foundation
Research Shows Pao Pereira, a Natural Plant Extract, Inhibits Cancer Stem Cells. - February 08, 2019 - The Beljanski Foundation
Paras Biopharmaceuticals Finland Oy Announces Successful Development of Biologically Active Romiplostim (N-Plate® Biosimilar) Production Technology
Paras Biopharmaceuticals Finland Oy today announced the achievement of a major milestone – the successful development of biologically active Romiplostim (N-Plate® biosimilar) production technology. Romiplostim has been produced with a proprietary and innovative continuous manufacturing... - January 31, 2019 - Paras Biopharmaceuticals Finland Oy
Hans Kaspersetz Joins Digital Pharma West Advisory Board
Digital Marketing Thought Leader to Help Craft Agenda for Leading Healthcare Marketing Conference. - January 25, 2019 - Arteric
Global OrthoBiologic Expands Its Operation Under the Name Global REGENERATIVE Group (GRG)
Global OrthoBiologic has announced today that it will expand its operation under the name Global REGENERATIVE Group (GRG) with headquarters to remain in Miami, Florida (globalregenerative.group) and will consist of 4 divisions, which will operate independently – Trade, Academy, Care and Finance. - January 16, 2019 - Global Regenerative Group
Bioquark Inc. and Ectocrine Technologies LLC to Collaborate on Mosquito-Derived Health Product Development
The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe. - January 12, 2019 - Bioquark Inc.
Kannaki Ramamoorthy Joins Arteric as Quality Assurance Manager
Software-Development Veteran Leads Team Renowned for Impeccable Standards. - December 21, 2018 - Arteric
Clinical Safety and Efficacy Data of DSP-Visulex Published in Current Eye Research
Aciont Inc. announced today that data from the clinical study of the DSP-Visulex technology is published online ahead of print in Current Eye Research. Reference: Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster CS, Montieth A, Higuchi JW, Brar B, Higuchi WI. Novel dexamethasone sodium phosphate treatment (DSP-Visulex) for noninfectious anterior uveitis: a randomized phase I/II clinical trial. Current Eye Research. - December 06, 2018 - Aciont Inc.
Silas Kim Joins Arteric as Talent Acquisition Manager
Fills talent pool at rapidly growing healthcare digital marketing agency - November 30, 2018 - Arteric
CrystalGenomics Signs Export Agreement with PharmArtis for Acelex in Russia
CrystalGenomics, Inc. announced today that they have signed an Export Agreement with PharmArtis International for the commercialization of Acelex® (polmacoxib) in Russia. Based on the terms of the agreement, CrystalGenomics will supply finished product of Acelex to PharmArtis and PharmArtis... - November 24, 2018 - CrystalGenomics, Inc.
Don Rodriguez Joins Arteric as Director, Analytics & Paid Search
Data Maven Brings a History of Double-Digit Growth in Client Revenue to a Growing Strategy, Analytics and Media Team. - November 16, 2018 - Arteric
Arteric to Present on Practical Applications of Artificial Intelligence (AI) in Healthcare Marketing
Two Case Studies Illustrate the Impact of AI on Accelerating Business, and the Insights That Result - November 07, 2018 - Arteric
Standigm Launches Artificial Intelligence-Driven Lead Optimization Service at BIO-Europe 2018 in Copenhagen, Denmark
Standigm, a company using the advanced AI technology to drug discovery, launched the customized lead optimization service, "Standigm BEST®," at BIO-Europe 2018 in Copenhagen, Denmark. Standigm BEST® provides AI-driven lead optimization and can also be utilized for fast-follow hit identification or patent fencing strategy. One-to-one meetings have been scheduled with leading pharmaceutical companies, indicating their interest in Standigm BEST®. - November 05, 2018 - Standigm
VIRUN® and Algarithm™ to Debut O3Omega™ NOT Peanut Butter and Jelly Sandwich Multi-serving Smoothies in Booth 1637 at Supply Side West Expo, Las Vegas on November 8 and 9
Virun® and Algarithm™ offer chill vibe at otherwise chaotic Supplyside West, serve up adult beverages enhanced with DHA and flavored like deserts, to debut new vegan O3Smoothies flavor, NOT Peanut Butter and Jelly. - November 02, 2018 - VIRUN
AdvantaPure(R) Introduces AdvantaSil(TM) Ultra Low Temperature Silicone Tubing That’s Engineered for Temperatures as Low as -112°C
New AdvantaSil Ultra Low Temperature Silicone Tubing is designed to aid pharmaceutical and biopharm manufacturers with protecting their high-value cell and drug products. The platinum-cured tubing is engineered for Single-Use applications involving cold storage and transport. It’s the first commercially-available tubing engineered for flexibility and crush resistance upon removal from a minus 86 degrees C freezer. A video on AdvantaPure’s website shows the test procedures and results. - November 01, 2018 - AdvantaPure